Open Label Phase II Study of MEN-10755 Administered Every 3 Weeks in Patients With Progressive Hormone Refractory Prostate Cancer
Phase of Trial: Phase II
Latest Information Update: 09 Sep 2016
At a glance
- Drugs Sabarubicin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 17 Feb 2009 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 21 Nov 2007 New trial record.